

Baiba K Gillard

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3605891/baiba-k-gillard-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

1,293
citations

21
h-index

34
g-index

57
ext. papers

1,449
ext. citations

4.7
avg, IF

4.13
L-index

#	Paper	IF	Citations
54	A solvent partition method for microscale ganglioside purification. <i>Analytical Biochemistry</i> , 1985 , 146, 220-31	3.1	160
53	Variable subcellular localization of glycosphingolipids. <i>Glycobiology</i> , 1993 , 3, 57-67	5.8	76
52	Measurement and significance of antibodies against GM1 ganglioside. Report of a workshop, 18 April 1989, Chicago, IL, U.S.A. <i>Journal of Neuroimmunology</i> , 1989 , 25, 255-9	3.5	76
51	Association of glycosphingolipids with intermediate filaments of human umbilical vein endothelial cells. <i>Experimental Cell Research</i> , 1991 , 192, 433-44	4.2	62
50	Association of glycosphingolipids with intermediate filaments of mesenchymal, epithelial, glial, and muscle cells. <i>Cytoskeleton</i> , 1992 , 21, 255-71		56
49	Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. <i>Scientific Reports</i> , 2017 , 7, 44624	4.9	54
48	Glycosphingolipids of human umbilical vein endothelial cells and smooth muscle cells. <i>Archives of Biochemistry and Biophysics</i> , 1987 , 256, 435-45	4.1	53
47	Decreased synthesis of glycosphingolipids in cells lacking vimentin intermediate filaments. <i>Experimental Cell Research</i> , 1998 , 242, 561-72	4.2	52
46	Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). <i>Journal of Lipid Research</i> , 2007 , 48, 348-57	6.3	50
45	Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1997-2006	9.4	41
44	Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning. <i>Biochemistry</i> , 2007 , 46, 7449-59	3.2	41
43	Serum opacity factor unmask human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. <i>Biochemistry</i> , 2007 , 46, 12968-78	3.2	38
42	Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009 , 1791, 1125-32	5	32
41	Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids. <i>Archives of Biochemistry and Biophysics</i> , 1990 , 279, 122-9	4.1	32
40	Pathways of glycosphingolipid biosynthesis in SW13 cells in the presence and absence of vimentin intermediate filaments. <i>Glycobiology</i> , 1996 , 6, 33-42	5.8	31
39	Isolation and purification of gangliosides from plasma. <i>Methods in Enzymology</i> , 1987 , 138, 300-6	1.7	31
38	ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 2260-2270	9.4	28

37	HDL superphospholipidation enhances key steps in reverse cholesterol transport. <i>Atherosclerosis</i> , 2010 , 209, 430-5	3.1	25
36	Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 849-856	4.9	24
35	Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. <i>Journal of Biological Chemistry</i> , 2017 , 292, 8864-8873	5.4	22
34	Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I. <i>Biochemistry</i> , 2009 , 48, 1481-7	3.2	22
33	Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 1714-21	9.4	21
32	Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 1834-41	9.4	21
31	Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. <i>Biochemistry</i> , 2009 , 48, 8070-6	3.2	18
30	Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. <i>Medicine and Science in Sports and Exercise</i> , 2013 , 45, 1043-50	1.2	17
29	Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol. <i>Biochemistry</i> , 2010 , 49, 9866-73	3.2	17
28	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 661-70	4.9	16
27	Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 1014-20	12.7	15
26	High-density lipoproteins, reverse cholesterol transport and atherogenesis. <i>Nature Reviews Cardiology</i> , 2021 , 18, 712-723	14.8	15
25	Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM. <i>Biophysical Journal</i> , 2016 , 110, 810-6	2.9	14
24	Biosynthesis of the blood group Pk and P1 antigens by human kidney microsomes. <i>Carbohydrate Research</i> , 1992 , 228, 277-87	2.9	13
23	Plasma factors required for human apolipoprotein A-II dimerization. <i>Biochemistry</i> , 2005 , 44, 471-9	3.2	12
22	Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism. <i>Methodist DeBakey Cardiovascular Journal</i> , 2016 , 12, 146-150	2.1	12
21	Cystic fibrosis serum pancreatic amylase. Useful discriminator of exocrine function. <i>American Journal of Diseases of Children</i> , 1984 , 138, 577-80		10
20	Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. <i>Methodist DeBakey Cardiovascular Journal</i> , 2019 , 15, 47-54	2.1	10

19	Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti-inflammatory effects. <i>Lipids</i> , 2010 , 45, 1117-26	1.6	9
18	Setting the course for apoAll: a port in sight?. <i>Clinical Lipidology</i> , 2013 , 8, 551-560		8
17	Serum amylase isoenzymes in cystic fibrosis patients. Evidence for a generalized defect in exocrine gland secretory regulation. <i>Pediatric Research</i> , 1980 , 14, 1168-72	3.2	8
16	Cholesterol determines and limits rHDL formation from human plasma apolipoprotein A-II and phospholipid membranes. <i>Biochemistry</i> , 2012 , 51, 8627-35	3.2	7
15	Free cholesterol determines reassembled high-density lipoprotein phospholipid phase structure and stability. <i>Biochemistry</i> , 2013 , 52, 4324-30	3.2	7
14	Alcohol: a nutrient with multiple salutary effects. <i>Nutrients</i> , 2015 , 7, 1992-2000	6.7	6
13	Properties of the products formed by the activity of serum opacity factor against human plasma high-density lipoproteins. <i>Chemistry and Physics of Lipids</i> , 2008 , 156, 45-51	3.7	5
12	N-Glycosylation is required for secretion-competent human plasma phospholipid transfer protein. <i>Protein Journal</i> , 2006 , 25, 167-73	3.9	5
11	Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism. <i>Biochemistry</i> , 2015 , 54, 2295-302	3.2	4
10	Streptococcal serum opacity factor promotes cholesterol ester metabolism and bile acid secretion in vitro and in vivo. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016 , 1861, 196-204	5	4
9	High-Density Lipoprotein Processing and Premature Cardiovascular Disease. <i>Methodist DeBakey Cardiovascular Journal</i> , 2015 , 11, 181-5	2.1	4
8	Neo High-Density Lipoprotein Produced by the Streptococcal Serum Opacity Factor Activity against Human High-Density Lipoproteins Is Hepatically Removed via Dual Mechanisms. <i>Biochemistry</i> , 2016 , 55, 5845-5853	3.2	4
7	Dietary Alcohol and Fat Differentially Affect Plasma Cholesteryl Ester Transfer Activity and Triglycerides in Normo- and Hypertriglyceridemic Subjects. <i>Lipids</i> , 2020 , 55, 299-307	1.6	2
6	Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020 , 1865, 158794	5	2
5	High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1 Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, e453-e467	9.4	1
4	Physico-chemical and physiological determinants of lipo-nanoparticle stability. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021 , 33, 102361	6	0
3	Structural Stability of Streptococcal Serum Opacity Factor. <i>Protein Journal</i> , 2017 , 36, 196-201	3.9	
2	High-Density Lipoprotein Therapies Then and Now 2015 , 545-555		

- 1 Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2016**, 1861, 1787-1795